Myeloma XI update: vorinostat/lenalidomide not a winning combination for maintenance
Lenalidomide monotherapy has proven to be an effective maintenance treatment for multiple myeloma (MM). Matthew Jenner, MBBS, MRCP, FRCPath, PhD, of University Hospital Southampton NHS Foundation Trus...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Alternative options for MM patients relapsing under lenalidomide
While the European Society for Medical Oncology (ESMO) provides guidelines for patient treatment after initial relapse, these are not always perfect. Speaking from the 1st European Myeloma Network (EM...
Author: VJHemOnc
Added: 07/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Lenalidomide maintenance remains best for newly diagnosed MM
Phase III trials EMN441 (NCT01091831) and EMN01 (NCT01093196) both investigated progression-free survival (PFS), overall survival (OS) and time to next treatment, in newly diagnosed multiple myeloma (...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Maintenance therapy for MRD negativity in MM
The RVD chemotherapy regimen combines lenalidomide, bortezomib, and dexamethasone, and is recognized by the European Society for Medical Oncology in its guidelines as the current standard therapy for ...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
FORTE: effective treatment of newly diagnosed MM with KRd
The FORTE trial (NCT02203643) aimed to compare responses to carfilzomib when combined with lenalidomide-dexamethasone (KRd) or with cyclophosphamide-dexamethasone (KCd) for newly diagnosed multiple my...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Data from MMY1001 Study | Update from Lenalidomide Refractory Subgroup
Ajai Chari, MD, Mt. Sinai discusses Data from MMY1001 Study | Update from Lenalidomide Refractory Subgroup at ASCO 2018
Author: Annual-Meeting
Added: 06/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 19, 2018 Category: Cancer & Oncology Source Type: podcasts
Adding to Lenalidomide to Make it Work Better Prednisone inhibitors, carfilzomib, and bortezomib
Paul G. Richardson, MD, explains Adding to Lenalidomide to Make it Work Better Prednisone inhibitors, carfilzomib, and bortezomib at Imedex Great Debates 2018.
Author: hematologydebates
Added: 05/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Combinations with RVD Beyond Daratumumab Data with ixazomib, revlimid, & dexamethasone
Paul G. Richardson, MD, explains Combinations with RVD Beyond Daratumumab Data with ixazomib, revlimid, & dexamethasone at Imedex Great Debates 2018.
Author: hematologydebates
Added: 05/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 10, 2018 Category: Cancer & Oncology Source Type: podcasts
RVD-Lite Mission Treating Over 50 Patients Regimen of Bortezomib, lenalidomide, steroids
Paul G. Richardson, MD, explains RVD-Lite Mission Treating Over 50 Patients Regimen of Bortezomib, lenalidomide, steroids at Imedex Great Debates 2018.
Author: hematologydebates
Added: 05/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - May 10, 2018 Category: Cancer & Oncology Source Type: podcasts
ADD-What impact do Revlimid (lenalidomide) and Pomalyst (pomalidomide) have on the bone marrow?
In this weeks video, Brian G.M. Durie explains that even though Revlimid and Pomalyst may reduce white blood cell counts, they do not permanently affect the bone marrow.<br /><br />BOTTOM LINE:<br />Revlimid and...
Author: InternationalMyelomaFoundation
Added: 03/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 26, 2018 Category: Cancer & Oncology Source Type: podcasts
ADD - Should the cost of Revlimid (lenalidomide) be reduced?
In this weeks video, Dr. Brian G.M. Durie addresses why the cost of patented drugs, such as Revlimid, have not yet been reduced.<br /><br />BOTTOM LINE:<br />The cost of drugs is important to all of the myeloma ...
Author: InternationalMyelomaFoundation
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Myeloma XI trial: lenalidomide maintenance therapy for multiple myeloma
At the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Graham Jackson, FRCP, FRCPath, MD, of Newcastle University, Newcastle, UK, was selected to present data f...
Author: VJHemOnc
Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Analysis from the Randomized Phase 3 Aspire Trial - Carfilzomib, Lenalidomide, & Dexamethasone V. Lenalidomide & Dexamethasone
Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses the analysis from the randomized phase 3 Aspire trial and Carfilzomib, Lenalidomide, & Dexamethasone V. Lenalidomide &...
Author: ASHReport
Added: 01/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Additional Combinations with Selinexor - Pomalidomide, Revlimid, Daratumumab
Michael Kauffman, MD from Karyopharm Therapeutics Inc discusses additional combinations with Selinexor & pomalidomide, revlimid, daratumumab at the 2017 American Society of Hematology.
Author: ASHReport
Added: 01/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 22, 2018 Category: Cancer & Oncology Source Type: podcasts
